Weiran Wang

Weiran Wang

Auto-generated profile, based on publicly available information

Weiran Wang

Department of Translational Medicine Genetron Health (Beijing) Technology, Co. Ltd. Beijing China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
MSMinke Shi
Minke Shi
WWWeiran Wang
Weiran Wang
JZJinku Zhang
Jinku Zhang
BLBobo Li
Bobo Li
DLDongxiao Lv
Dongxiao Lv
TMtonghui ma
tonghui ma
Fusion of RET with different partner genes has been detected in papillary thyroid, lung, colorectal, pancreatic, and breast cancer. Approval of selpercatinib for treatment of lung and thyroid cancer with RET gene mutations or fusions calls for studies to explore RET fusion partners and their eligibility for RET‐based targeted therapy. In this study, RET fusion patterns in a large group of Chinese cancer patients covering several cancer types were identified using next‑generation sequencing. A total of 44 fusion patterns were identified in the study cohort with KIF5B, CCDC6, and ERC1 being the most common RET fusion partners. Notably, 17 novel fusions were first reported in this study. Prevalence of functional RET fusions was 1.05% in lung cancer, 6.03% in thyroid cancer, 0.39% in colorectal cancer, and less than 0.1% in gastric cancer and hepatocellular carcinoma. Analysis showed a preference for fusion partners in different tumor types, with KIF5B being the common type in lung cancer, CCDC6 in thyroid cancer, and NCOA4 in colorectal cancer. Co‐occurrence of EGFR mutations and RET fusions with rare partner genes (rather than KIF5B) in lung cancer patients was correlated with epidermal growth factor receptor‐tyrosine kinase inhibitor resistance and could predict response to targeted therapies. Findings from this study provide a guide to clinicians in determining tumors with specific fusion patterns as candidates for RET targeted therapies.

1 November 2020 in Protein Expression and Purification
Verified
Journal Article
Closed access
MQMeng Qu
Meng Qu
WWWeiran Wang
Weiran Wang
WLWeiting Li
Weiting Li
JCJiaming Cao
Jiaming Cao
CWChu Wang
Chu Wang
XYXianghui Yu
Xianghui Yu